| Year |
Citation |
Score |
| 2023 |
Vail ME, Farnsworth RH, Hii L, Allen S, Arora S, Anderson RL, Dickins RA, Orimo A, Wu SZ, Swarbrick A, Scott AM, Janes PW. Inhibition of EphA3 Expression in Tumour Stromal Cells Suppresses Tumour Growth and Progression. Cancers. 15. PMID 37760615 DOI: 10.3390/cancers15184646 |
0.337 |
|
| 2020 |
Janes PW, Vail ME, Gan HK, Scott AM. Antibody Targeting of Eph Receptors in Cancer. Pharmaceuticals (Basel, Switzerland). 13. PMID 32397088 DOI: 10.3390/Ph13050088 |
0.38 |
|
| 2016 |
Atapattu L, Saha N, Chheang C, Eissman MF, Xu K, Vail ME, Hii L, Llerena C, Liu Z, Horvay K, Abud HE, Kusebauch U, Moritz RL, Ding BS, Cao Z, et al. An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth. The Journal of Experimental Medicine. PMID 27503072 DOI: 10.1084/Jem.20151095 |
0.431 |
|
| 2014 |
To C, Farnsworth RH, Vail ME, Chheang C, Gargett CE, Murone C, Llerena C, Major AT, Scott AM, Janes PW, Lackmann M. Hypoxia-controlled EphA3 marks a human endometrium-derived multipotent mesenchymal stromal cell that supports vascular growth. Plos One. 9: e112106. PMID 25420155 DOI: 10.1371/Journal.Pone.0112106 |
0.369 |
|
| 2014 |
Janes PW, Slape CI, Farnsworth RH, Atapattu L, Scott AM, Vail ME. EphA3 biology and cancer. Growth Factors (Chur, Switzerland). 32: 176-89. PMID 25391995 DOI: 10.3109/08977194.2014.982276 |
0.333 |
|
| 2014 |
Vail ME, Murone C, Tan A, Hii L, Abebe D, Janes PW, Lee FT, Baer M, Palath V, Bebbington C, Yarranton G, Llerena C, Garic S, Abramson D, Cartwright G, et al. Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment. Cancer Research. 74: 4470-81. PMID 25125683 DOI: 10.1158/0008-5472.Can-14-0218 |
0.456 |
|
| 2012 |
Atapattu L, Saha N, Llerena C, Vail ME, Scott AM, Nikolov DB, Lackmann M, Janes PW. Antibodies binding the ADAM10 substrate recognition domain inhibit Eph function. Journal of Cell Science. 125: 6084-93. PMID 23108669 DOI: 10.1242/Jcs.112631 |
0.329 |
|
| 2010 |
Nievergall E, Janes PW, Stegmayer C, Vail ME, Haj FG, Teng SW, Neel BG, Bastiaens PI, Lackmann M. PTP1B regulates Eph receptor function and trafficking. The Journal of Cell Biology. 191: 1189-203. PMID 21135139 DOI: 10.1083/Jcb.201005035 |
0.338 |
|
| 2002 |
Pierce RH, Vail ME, Ralph L, Campbell JS, Fausto N. Bcl-2 expression inhibits liver carcinogenesis and delays the development of proliferating foci. The American Journal of Pathology. 160: 1555-60. PMID 12000706 DOI: 10.1016/S0002-9440(10)61101-7 |
0.677 |
|
| 2002 |
Vail ME, Chaisson ML, Thompson J, Fausto N. Bcl-2 expression delays hepatocyte cell cycle progression during liver regeneration. Oncogene. 21: 1548-55. PMID 11896583 DOI: 10.1038/Sj.Onc.1205212 |
0.472 |
|
| 2002 |
Sprenger CC, Vail ME, Evans K, Simurdak J, Plymate SR. Over-expression of insulin-like growth factor binding protein-related protein-1(IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis. Oncogene. 21: 140-7. PMID 11791184 DOI: 10.1038/Sj.Onc.1205021 |
0.423 |
|
| 2001 |
Adams ML, Pierce RH, Vail ME, White CC, Tonge RP, Kavanagh TJ, Fausto N, Nelson SD, Bruschi SA. Enhanced acetaminophen hepatotoxicity in transgenic mice overexpressing BCL-2. Molecular Pharmacology. 60: 907-15. PMID 11641418 DOI: 10.1124/Mol.60.5.907 |
0.615 |
|
| 2001 |
Vail ME, Pierce RH, Fausto N. Bcl-2 delays and alters hepatic carcinogenesis induced by transforming growth factor alpha. Cancer Research. 61: 594-601. PMID 11212255 |
0.64 |
|
| Show low-probability matches. |